These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37301953)

  • 21. Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.
    López-Castro T; Sohler N; Riback L; Bravo G; Ohlendorf E; Ghiroli M; Fox AD
    Harm Reduct J; 2024 Jun; 21(1):108. PubMed ID: 38824597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
    Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
    Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder.
    Tabatabaeepour N; Morgan JR; Jalali A; Kapadia SN; Meinhofer A
    J Subst Abuse Treat; 2022 Sep; 140():108800. PubMed ID: 35577664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.
    Krawczyk N; Allen ST; Schneider KE; Solomon K; Shah H; Morris M; Harris SJ; Sherman SG; Saloner B
    Harm Reduct J; 2022 Aug; 19(1):95. PubMed ID: 36002850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.
    Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE
    Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571
    [No Abstract]   [Full Text] [Related]  

  • 29. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial.
    Gustafson DH; Landucci G; Vjorn OJ; Gicquelais RE; Goldberg SB; Johnston DC; Curtin JJ; Bailey GL; Shah DV; Pe-Romashko K; Gustafson DH
    Am J Psychiatry; 2024 Feb; 181(2):115-124. PubMed ID: 37789744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States.
    Lambdin BH; Bluthenthal RN; Tookes HE; Wenger L; Morris T; LaKosky P; Kral AH
    Drug Alcohol Depend; 2022 Aug; 237():109504. PubMed ID: 35688052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington.
    Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM
    Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907
    [No Abstract]   [Full Text] [Related]  

  • 34. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
    Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
    Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
    [No Abstract]   [Full Text] [Related]  

  • 35. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs.
    Lambdin BH; Kan D; Kral AH
    Subst Abuse Treat Prev Policy; 2022 Jul; 17(1):51. PubMed ID: 35841036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
    Michener PS; Evans EA; Ferguson WJ; Friedmann PD
    Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF; Prevedel S; Light T; Sulzer SH
    Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.